Miruvor
Sign up
The short answer

What studies of Methylphenidate (Ritalin, Concerta) found

16papers on Methylphenidate (Ritalin, Concerta)
74people in 7 studies testing Methylphenidate (Ritalin, Concerta) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Mixed results

Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.

5 outcomes rated · see each below

ME/CFS: B May help

Based on the strongest evidence, the placebo trial (low certainty): 3 findings, all B.

10 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies of Methylphenidate (Ritalin, Concerta) disagree, so it’s not clear whether it helps. For ME/CFS, Methylphenidate (Ritalin, Concerta) may help, but the evidence is still limited. For long COVID and ME/CFS studied together, Methylphenidate (Ritalin, Concerta) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 16 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Methylphenidate (Ritalin, Concerta) · ME/CFS is hereB
    May helpImprovement, low certainty
  3. Methylphenidate (Ritalin, Concerta) · Long COVID is hereMethylphenidate (Ritalin, Concerta) · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Cognition (brain fog)2 studies · 7 (few people) people took Methylphenidate (Ritalin, Concerta) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (7 in all); the studies disagree.

Studies with no comparison group2 studies · 7 people with results (few people)

Studies disagree about cognition (brain fog).

Studies disagree about whether methylphenidate (Ritalin, Concerta) helps cognition (brain fog). Mixed results · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (7 in all)
  • The studies disagree
See the 2 studies
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    5 mg/day and increased to 10 mg TID; 10 mg at 5 AM
    Outcome
    Effectiveness of LDX 60 mg versus 70 mg
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog). (2024)

    People in the study
    6 in the study
    Dose
    5 - 20 mg, instructed to take it in the morning
    Outcome
    HVLT immediate recall Hopkins verbal learning test
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep2 studies · 2 (few people) people took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (2 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 2 people with results (few people)

Sleep improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (2 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    5 mg/day and increased to 10 mg TID; 10 mg at 5 AM
    Outcome
    Insomnia with trazodone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. 1171 Hypersomnia Secondary to Long Covid (2024)

    People in the study
    1 in the study
    Dose
    up to 36mg ER
    Outcome
    sleep inertia
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · 5 mg/day and increased to 10 mg TID; 10 mg at 5 AM (few people)

Fatigue improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    5 mg/day and increased to 10 mg TID; 10 mg at 5 AM
    Outcome
    Fatigue with LDX
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 5 (few people) people took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (5 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 5 people with results (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (5 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    5 mg/day and increased to 10 mg TID; 10 mg at 5 AM
    Outcome
    Overall treatment response
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Methylphenidate in COVID-19 Related Brain Fog: A Case Series (2024)

    People in the study
    4 in the study
    Dose
    20 mg (case 1), 20 mg (case 2), 30 mg (case 3), 10 mg (case 4), continued for 1 month after the review visit and was then tapered down by 5 mg every week and then stopped for cases 1, 3, and 4; Case 2 stopped taking methylphenidate after 1 month
    Outcome
    symptoms subjectively
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning2 studies · 2 (few people) people took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (2 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 2 people with results (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (2 in all)
  • Not all results were tested against chance
See the 2 studies
  1. 1171 Hypersomnia Secondary to Long Covid (2024)

    People in the study
    1 in the study
    Dose
    up to 36mg ER
    Outcome
    return to school full time and reached normal functioning
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    5 mg/day and increased to 10 mg TID; 10 mg at 5 AM
    Outcome
    Medication coverage across all hours
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

ME/CFS

Symptoms

Fatigue2 studies · 61 people took Methylphenidate (Ritalin, Concerta) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (60 in all).

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

Fatigue improved more than in the comparison group.

Methylphenidate (Ritalin, Concerta) may reduce fatigue in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (60 in all)

Studies with no comparison group1 in the study · After 1 month of therapy · 18 mg/day, added to his treatment (few people)

Fatigue improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    VAS fatigue Visual Analogue Scale (VAS)
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021)

    People in the study
    1 in the study
    Dose
    18 mg/day, added to his treatment
    Outcome
    drowsiness and fatigue
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 60 people took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (60 in all).

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on cognition (brain fog) in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (60 in all)
See the 1 study
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    Concentration Checklist Individual Strength (CIS)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    High
Autonomic symptoms1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After 1 month of therapy · 18 mg/day, added to his treatment (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on autonomic symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021)

    People in the study
    1 in the study
    Dose
    18 mg/day, added to his treatment
    Outcome
    dizziness
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep2 studies · 61 people took Methylphenidate (Ritalin, Concerta) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 60 people found no clear difference; a small benefit can't be ruled out.

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

No clear difference in sleep.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on sleep in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 60 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group1 in the study · After 1 month of therapy · 18 mg/day, added to his treatment (few people)

Sleep improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on sleep in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    VAS sleeping disturbance Visual Analogue Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021)

    People in the study
    1 in the study
    Dose
    18 mg/day, added to his treatment
    Outcome
    total sleep duration
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 60 people took Methylphenidate (Ritalin, Concerta) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 60 people found no clear difference; a small benefit can't be ruled out.

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    VAS happiness Visual Analogue Scale (VAS)
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Pain1 study · 60 people took Methylphenidate (Ritalin, Concerta) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 60 people found no clear difference; a small benefit can't be ruled out.

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

No clear difference in pain.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on pain in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    Bodily pain Medical Outcome Study Short-Form 36 items
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Post-exertional malaise1 study · 60 people took Methylphenidate (Ritalin, Concerta) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 60 people found no clear difference; a small benefit can't be ruled out.

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

No clear difference in post-exertional malaise.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on post-exertional malaise in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    VAS post-exertional malaise Visual Analogue Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning2 studies · 61 people took Methylphenidate (Ritalin, Concerta) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (60 in all).

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

Daily functioning improved more than in the comparison group.

Methylphenidate (Ritalin, Concerta) may improve daily functioning in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (60 in all)

Studies with no comparison group1 in the study · After 1 month of therapy · 18 mg/day, added to his treatment (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    Activity Checklist Individual Strength (CIS)
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021)

    People in the study
    1 in the study
    Dose
    18 mg/day, added to his treatment
    Outcome
    school life and sleep rhythm
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 60 people took Methylphenidate (Ritalin, Concerta) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (60 in all).

The placebo trial60 randomised · 1 month · 10 mg taken twice daily, at 8 AM and 2 PM

Quality of life improved more than in the comparison group.

Methylphenidate (Ritalin, Concerta) may improve quality of life in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (60 in all)
See the 1 study
  1. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? (2006)

    People in the study
    60 randomised
    Dose
    10 mg taken twice daily, at 8 AM and 2 PM
    Outcome
    Physical factor Medical Outcome Study Short-Form 36 items (SF-36)
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · After 1 month of therapy · 18 mg/day, added to his treatment (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021)

    People in the study
    1 in the study
    Dose
    18 mg/day, added to his treatment
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Both together

Symptoms

Autonomic symptoms1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    peak heart rate when walking on cromolyn
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Pain improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on pain in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    remaining symptoms at one year
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Too little to say about cognition (brain fog).

Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Too little to say about fatigue.

Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    energy and overall function on naltrexone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Methylphenidate (Ritalin, Concerta) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of methylphenidate (Ritalin, Concerta) on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    symptom improvement over 30 months
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects2 studies
Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue2 studies
Trouble sleeping1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 to 36 mg at the start in most studies

  2. 2Raise

    Raised step by step in 5 of 9 studies

  3. 3Top dose

    Most often 20 mg (3 of 9 studies)

Doses across 9 studies

5 to 54 mg.

Each study’s dose, as printed

All papers

  1. Long-term methylphenidate intake in chronic fatigue syndrome.2016 · compared with another group · 233 in the study · 144 with outcome data
    Summary

    This observational questionnaire study evaluated the effect of long-term methylphenidate on fatigue, concentration and daily activities in chronic fatigue syndrome (CFS) with concentration difficulties. A total of 233 consecutive CFS patients advised to try methylphenidate were identified; 194 received the questionnaire, 149 (76.8%) returned it, and data from 144 were analyzed. Patients were prescribed methylphenidate starting at 10 mg twice daily, with advice to increase to 20 mg twice daily if needed; this report concerns long-term intake at the time of the questionnaire. Outcomes were patient-reported, comparing 50 patients who continued methylphenidate with 94 who stopped, not a placebo group. At questionnaire time, 65.3% had stopped methylphenidate and 34.7% still took it daily or occasionally. Among the 50 who continued, 48% reported at least 50% improvement of fatigue and 62% at least 50% improvement of concentration difficulties; 68% could handle more household tasks, 16 of 21 with a job (76%) functioned better at work, 5 (10%) resumed their job, and 9 out of 10 students reported help studying. Twenty-seven of 50 continuing patients reported no side effects; 23 (46%) reported any side effect. In those who stopped, 78 (83%) reported any side effect; side effects were more frequent in stopped patients (p < 0.001), including agitation (p = 0.004) and palpitations (p < 0.001). Increased fatigue was reported by 2 (4%) continuing patients and 18% of stopped patients. Median maximal daily dose did not differ (15.0 mg vs 12.5 mg; p = 0.61).

  2. A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.2025 · case report · 1 in the study
    Summary

    This case report describes one 35-year-old Japanese woman with Chronic Fatigue Syndrome (CFS) who had experienced chronic fatigue since the age of 11 years. No comparison group was reported; the report describes a within-person clinical course over four years. The patient was treated with modafinil and methylphenidate beginning in 2012, levocarnitine at 1500 mg daily from November 2018, ubiquinone at 30 mg/day, and oral 5-ALA/SFC starting at 100 mg/day in January 2021. The 5-ALA/SFC dose was increased by 200 mg daily in February, to 300 mg/day in April 2021, and to 400 mg/day in January 2022; later attempts to reduce the dose in August 2022 to 200, 100, and 50 mg resulted in a significant decline in various activities. Outcomes included daily activities, mobility, psychosocial functioning, symptoms and quality of life, FACIT-F scores over time, daytime activity, daily functioning, various activities, sleep disturbances, and depression symptoms. The report states that 5-ALA/SFC led to significant improvements in daily activities, mobility, and psychosocial functioning; that the treatment regimen augmented with 5-ALA/SFC and ubiquinone led to significant improvements in symptoms and quality of life; and that returning to the 400 mg dose markedly improved all scores. Modafinil and methylphenidate proved ineffective for sleep disturbances, and antidepressants failed to improve depression symptoms. The patient continued 5-ALA/SFC for 4 years with no apparent adverse events; mild fever and chest discomfort were also reported. No withdrawals due to harms were recorded. Limitations include unavailable paternal DNA, uncertainty about the heterozygous mutation and CFS, and unclear long-term safety of 5-ALA/SFC.

  3. Post-COVID central hypersomnia, a treatable trait in long COVID: 4 case reports.2024 · case report · 530 in the study · 4 started · 4 with outcome data
    Summary

    This paper reports four case reports from a post-COVID clinic that evaluated 530 patients referred between May 2021 and January 2023 and covered a population of around 300,000 inhabitants. The four patients had post-COVID central hypersomnia after polymerase chain reaction-confirmed SARS-CoV-2 infection; three met criteria for idiopathic hypersomnia and one for type II narcolepsy. Sleep studies and sleep latency tests were performed. Three patients were prescribed methylphenidate: 40 mg/d in Patient 1, 20 mg/d in Patient 2, and 10 mg/three times daily in Patient 4 (taken only on days when work required more concentration, about 3 times/week). Patient 2 later tapered to 10 mg/d and stopped gradually after 2 months with no recurrence of hypersomnia. The paper reports a favorable response to methylphenidate in three cases and spontaneous resolution in one case. Patient 1's sleep requirements decreased back to 8–9 h/day from up to 12–14 h per day, and he returned to school. Patient 2 was able to return to work with 20 mg/d. Patient 4 had a good effect on sleepiness. One harm was recorded: a trial to stop methylphenidate in Patient 1 failed after 4 months with a resurgence of hypersomnia (sleep duration more than 11 h per day). There was no comparison group. The authors state that the causal link is not formally proven and the small number of cases limits conclusions about treatment and evolution.

  4. Methylphenidate in COVID-19 Related Brain Fog: A Case Series2024 · case report · 4 in the study
    Summary

    This case series described 4 patients with post-COVID brain fog persisting more than 12 weeks after infection, assessed by two psychiatrists in a psychiatric facility. Methylphenidate was given to all 4 patients for fatigue symptoms: 20 mg for case 1, 20 mg for case 2, 30 mg for case 3, and 10 mg for case 4. It was continued for 1 month after the review visit and then tapered by 5 mg every week and stopped for cases 1, 3, and 4; case 2 stopped taking methylphenidate after 1 month. There was no control group. Outcomes were the Fatigue Severity Scale (FSS) and Mini Mental Status Examination (MMSE) at baseline, at post-intervention review, and at 3- and 6-month follow-up. All patients showed improvement in symptoms subjectively and objectively within 2–4 weeks. FSS fell from 39 to 9 in case 1, 38 to 9 in case 2, 40 to 9 in case 3, and 37 to 9 in case 4; MMSE rose from 28 to 30, 29 to 30, 27 to 30, and 28 to 30, respectively. The authors reported no relapse at follow-ups and that improvement persisted at follow-up without extended treatment.

  5. 1171 Hypersomnia Secondary to Long Covid2024 · case report · 1 in the study
  6. Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog).2024 · case report · 6 in the study
    Summary

    Six patients with functionally limiting post-COVID cognitive dysfunction (PCCD) at the Johns Hopkins Post-Acute COVID-19 Team clinic were treated with methylphenidate 5 - 20 mg in routine care and followed for 4 to 8 weeks; Table 2 lists treatment durations from 10 days to 1 year and a 3-week follow-up interval for one patient. There was no comparison group; outcomes were subjective cognitive dysfunction and an objective cognitive battery before and after treatment. Three out of the six patients reported subjective improvement, one described it as “notable” and another as “marked” improvement in memory and concentration. The authors reported statistically significant pre/post differences for HVLT immediate recall (mean difference 3.3, 95% CI 1.02 - 5.64, P = 0.006) and HVLT delayed recall (mean difference 1.0, 95% CI 0.75 - 1.93, P = 0.019), and a difference for category-cued verbal fluency (mean difference 3.3, 95% CI 0.89 - 7.56, P = 0.05). They reported no significant differences for HVLT delayed recognition (P = 0.35), Oral trail A (P = 0.93), Oral trail B (P = 0.79), or letter-cued verbal fluency (P = 0.36). Four of six patients did not report adverse effects; two complained of gastric upset and increased fatigue, and one discontinued methylphenidate due to adverse effects. One patient was advised to stop all psychiatric medications after starting clopidogrel for drug-drug interaction concerns. The authors state the dose was low (5 to 20 mg per day) and the sample was very small.

  7. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · case report · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  8. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report.2023 · case report · 1 in the study
    Summary

    A single case study reports a 61-year-old man with Post-COVID-19 Syndrome (PCS) or Long COVID, treated on an outpatient basis and self-referred. He received Immediate-Release Methylphenidate (IR-MPH) started at 5 mg/day and increased to 10 mg TID, then Lisdexamfetamine (LDX) 30 mg upon waking, doubled to 60 mg and soon to 70 mg, with Bupropion XL up to 300 mg/day. The PCS treatment lasted 18 months. ADHD-like symptoms were measured with the Adult ADHD Self-Report Screening Scale (ASRS; total score 0 to 72). Baseline ASRS was 40. IR-MPH initially reduced symptoms to 28 points (30% reduction from baseline); ASRS returned to baseline (40 points) after IR-MPH interruption. Fatigue was fully treated with LDX, but ADHD-like symptoms remained unchanged after some weeks; there was no difference in effectiveness between 60 or 70 mg of LDX. A split LDX plus IR-MPH scheme used for 1 month reduced ASRS to 25 points (37,5% reduction from baseline). After 5 weeks, bupropion add-on reduced ASRS to 17 from the baseline 40 points, a 57,5% reduction and remission of symptoms since the cutoff is 24 points. The final drug combination remained well tolerated. The only adverse effect of the final drug combination was a weight loss of 5 kg that did not disturb the patient; increasing IR-MPH doses was not well tolerated due to insomnia, and the patient did not experience side effects with LDX. Authors state limitations are inherent to a case study and that replication in more patients with PCAS is needed.

  9. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report2021 · case report · 1 in the study
    Summary

    This case report describes one 16-year-old male adolescent hospitalized with intermittent dizziness, drowsiness, and fatigue for approximately 2 years, diagnosed with chronic fatigue syndrome with narcolepsy, POTS, and hyperhomocysteinemia associated with MTHFR mutation. There was no comparison group. He was given oral folate 5 mg/day, vitamin B6 10 mg/day, vitamin B12 0.5 mg/day, and l-carnitine 1 g/day continuously; oral midodrine hydrochloride 7.5 mg/day was added. After 1 month of therapy, the report states dizziness was relieved to a certain extent, but drowsiness and fatigue barely improved. Methylphenidate hydrochloride tablets 18 mg/day were then added. After another month, the patient felt much less drowsy during the daytime, and total sleep duration shortened to 9 to 10 h/day from a reported 14 to 15 h/day. He began to gradually resume school life and maintained a normal sleep rhythm since then. The report also states narcoleptic symptoms were controlled by methylphenidate hydrochloride and symptoms improved after the combined therapy. No harms or withdrawals were reported. The authors state that the mechanisms by which MTHFR gene polymorphism plays a role in CFS still need to be studied.

  10. Proceedings #19. Maintenance tDCS: A Case of Full and Durable Recovery from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)2017 · case report · 1 in the study
    Summary

    This conference proceeding reports a case report of one 61-year-old man with treatment-resistant progressive ME/CFS who was referred for neuromodulation. There was no comparison group. He was trained in the office and then self-administered tDCS at home daily, with anode on the left dorsolateral prefrontal cortex, cathode on the right dorsolateral prefrontal cortex, 2 mA/min, 20 minutes, 40 mA total dose, using 1.5” diameter electrode pads. After four weeks, sessions were increased to twice daily (6 AM and 12 Noon). Modafinil 200 mg provided partial relief of fatigue; later the dose was lowered to 100 mg due to insomnia, and modafinil was stopped but resumed at 100 mg daily after he felt less well. The paper reports one year of maintenance tDCS and follow-up neurophysiological studies 14 months after initial presentation. It reports significant benefit early in the day during the first month of daily tDCS, consistent benefit after twice-daily sessions, and full clinical recovery over the next few months, with improved exercise tolerance and a return to physical exercise several times each week. Before treatment, omission errors were 14.29%; after treatment, behavioral measures were within the normal rage and there were no omission errors. The patient reported sustained relief. The authors state that data were not shown for frontocentral infra-slow frequency drift.

  11. Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder.2013 · case report · 3 in the study
    Summary

    This case series describes 3 patients with chronic fatigue syndrome who were referred for psychiatric consultation and evaluated at the Rochester Center for Behavioral Medicine outside of Detroit, MI. All 3 began long-acting psychostimulant medication. Irene (Patient 1) received osmotic-controlled release oral delivery system (OROS®) methyl phenidate tablets (Concerta®), titrated to 54 mg/morning. Katherine (Patient 2) received amphetamine/dextroamphetamine extended-release tablets (Adderall XR®) at 30 mg/morning. Alice (Patient 3) received lisdexamfetamine (Vyvanse®), starting at 30 mg/morning and titrated from 30 mg/morning to 70 mg/morning over a 6-week period. Katherine and Alice continued antidepressant medications. The Fatigue Severity Scale and Epworth Sleepiness Scale were repeated 4 weeks after the beginning of stimulant treatment. After treatment with psychostimulants, the 3 patients reported improved symptoms of fatigue and pain, and cognitive and core ADHD symptoms; with psychostimulant treatment, all 3 noted marked improvement of fatigue and cognitive symptoms. Fatigue Severity Scale scores were 60 to 30 for Irene, 56 to 34 for Katherine, and 58 to 24 for Alice. Epworth Sleepiness Scale scores were 7 to 7 for Irene, 10 to 6 for Katherine, and 11 to 9 for Alice. There was no comparison group and no randomisation. Harms were not reported. The authors state this is a preliminary finding and further research is needed before recommendations.

  12. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

  13. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime